The drumbeat of Alzheimer’s PhIII failures continues as vTv drug is outperformed by a placebo, shares crash
The execs at vTv $VTVT have put another nail in the coffin of recycled Alzheimer’s drug programs.
The biotech, which floated an IPO on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
